Mitre.org- New Un-vaccines use immortalized B cells- just like LYMErix Disease!
Mort Zuckerman
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com
Subject: Mitre.org- New Un-vaccines use immortalized B cells- just
like LYMErix Disease!
Date: Nov 18, 2009 8:01 AM
ARTICLE BELOW
=======================
See, what happens is, OspA
inhibits the autokill kinases,
rendering Epstein-Barr latently
infected cells to become unlatent...
and end up immortalized or mutated
as explained and *SHOWN* (not for
the Aspergery type of males like
Fauci, psychiatrists and lawyers
who have no maleness) in the Pam3Cys
immunosuppression explainer:
http://www.actionlyme.org/Pam3Cys_Version15.htm
Or use the Talkie-Version:
http://www.lymecryme.com/rich_text_21.html
Now, here, below, is a company applying
that technology, like the other
set of people applying the Pam3Cys
immunosuppression/immortalization
technology for nerve regeneration:
http://www.ncbi.nlm.nih.gov/pubmed?term=19661221[uid]&cmd=DetailsSearch&log$=details
"CONCLUSION: Pam3Cys may be a suitable agent for stimulating CNS
regeneration."
See. If this Yale clique had not been
such evil, vicious, lying criminal
arseholes, these amazing discoveries
could have been theirs.
A treatment for HIV, Malaria and
tuberculosis/Lyme... The New
Stem Cells for nerve damage...
ROTFLMAO
Now Yale and UConn are nearly completely
defunded instead keeping their FRAUDULENT
empire of tick borne diseases vaccines
and test kits... and the $$$ millions in
royalties they expected every year from
LYMErix alone:
http://www.youtube.com/watch?v=yS9-B7G3Ha8
KMDickson
===================================
http://www.mitre.org/news/digest/advanced_research/11_09/vaccination.html
Beyond Vaccination: A New Platform for Treating Infectious Disease
November 2009
Beyond Vaccination: A New Platform for Treating Infectious Disease
Influenza pandemics have struck three times—1918, 1957, and 1968—and
each outbreak claimed the lives of millions of people around the
world. Earlier this spring, the World Health Organization raised the
threat of H1N1 (swine flu) to pandemic level. Another more lethal flu
(H5N1 or avian flu) has also been identified in recent years as having
the potential to cause a pandemic that could overwhelm healthcare
systems, kill hundreds of millions of people, and result in widespread
financial losses from ensuing quarantines.
As a countermeasure against flu pandemics and other biological
threats, a MITRE-sponsored research program ("Development of Human
Monoclonal Antibodies for Neutralization of Avian Influenza Virus and
for Use in Diagnosis") is working on therapies for flu victims. Juan
Arroyo, a lead scientist in our Department of Defense federally funded
research and development center, and his team—in collaboration with
the Medical University of South Carolina (MUSC)—have developed an
innovative method for the treatment of infectious diseases such as the
flu.
Vaccine Readiness?
Existing vaccines help prevent a small percentage of the disease
threats affecting humans. In the case of flu viruses, new vaccines are
being developed and deployed every year to combat the continuously
evolving flu pathogens. Current methods for producing flu vaccines
rely on virus production in eggs. These methods are costly and time
consuming and typically cannot generate a sufficient number of doses
to protect a large population in situations where a disease threat
occurs rapidly or unexpectedly. While vaccines are considered the best
preventive measure, they usually do not work if administered
subsequent to exposure to the pathogen. In the event of a pandemic,
it's estimated that current rates of conventional vaccine production
only allow for the vaccination of 20 percent of the population before
the majority of the population has been exposed to infection.
The Monoclonal Antibody Team
MITRE researchers, in collaboration with the Medical University of
South Carolina, have spent three years developing an innovative
technology platform for producing new antibody treatments for
infectious diseases. In addition to project leader Juan Arroyo, the
MITRE monoclonal antibody team includes Heath Farris, Steve Stratman,
Cinde Daigneau, Robert Snow, Fred Steinberg, and Tom McEntee.
Arroyo and his team devised a new approach to developing therapies for
infectious diseases, such as flu, based on the production of human
monoclonal antibodies. As explained by Fred Steinberg, a senior
advisor to the program, "The method uses B cells obtained from human
tonsils that are driven to differentiate into antibody forming cells."
B cells are one of the cell types found in blood and lymphoid organs.
They start as immature ("naïve") cells and must undergo several
transformations before they can produce useful antibodies.
MITRE research has demonstrated that naïve B cells of human origin can
be manipulated to produce antibodies able to bind to specific
pathogens. "In this process, we introduced B cells into a
transformation course that turns them into immortalized cells that can
grow indefinitely outside the body," says Arroyo. "We then selected
from that population of cells those that are generating antibodies
that bind to our target." From the total population of B cells in each
individual, at least a few are able to recognize almost any given
pathogenic agent.
The method—known as antibody therapy—is a promising alternative to
vaccination. "Not only do protective antibodies have preventive power,
they also can inhibit the pathogen's ability to cause disease even
when administered subsequent to exposure," says Arroyo. Therefore, a
rapid method for producing protective antibodies would have an
immediate impact on protection from infectious diseases. The
successful isolation of B cell clones generating antibodies against
H5N1 suggests we can generate antibodies against new pathogen threats
as they appear.
The speed of developing these antibody-based therapeutics represents a
significant advantage over technologies currently employed to develop
vaccines. Monoclonal antibodies have yielded dramatic therapeutic
benefits in cancer treatment worldwide. This same power has been used
to bind and neutralize toxins, viruses, and bacteria.
Tonsil Tissue
To obtain human B cells, the research team gets human tonsil tissue
from children undergoing tonsillectomies. Tonsils are an excellent
source because 109 white blood cells can be obtained from an average
tonsil, about half of which are human B cells. "It's important to note
that the antibodies produced with this technology are cost effective
and 100 percent of human origin," says Arroyo. In the past, animal
antibodies were given to people; however, recipients often developed
"serum sickness" from the foreign proteins. These potentially
dangerous side effects are avoided by using antibodies from human
origins. Human antibodies are not seen as foreign substances by the
human immune system.
In October 2008, the technology was transferred from MUSC to the
Biotechnology/Nanotechnology Laboratory at MITRE after methods to
induce antibody production and selection of B cell clones were
defined. This milestone not only established the bio/nano lab as a
facility for antibody production, but also supports the
transferability of MITRE's technology into other labs (including
government-designated sites) for production. At MITRE, methods were
developed to isolate B cells effective against other pathogenic
viruses.
Another milestone occurred in June when Arroyo's team had success in
increasing the scale of production of antibodies against H5N1. The
MITRE lab now can generate antibodies for efficacy testing of binding
to flu viruses. "We plan to perform in-vitro neutralization testing
within our MITRE-sponsored research budget, and testing in
collaboration with the National Institute of Allergy and Infectious
Disease of the National Institutes of Health beyond those funds," says
Arroyo.
National Security Stockpile
In addition to potential widespread civilian uses for combating
infectious disease, monoclonal antibody research is expected to have
biodefense-related applications. Even though a vaccine for the avian
flu H5N1 exists in emergency stockpiles, these therapeutic monoclonal
antibodies would be of interest to the biodefense and public health
communities. With cost-effective manufacturing, this technology can
provide a fast and deployable countermeasure against avian flu and
other biothreats.
Since a new vaccine requires time for development, testing, and
approval for use by the Food and Drug Administration, it can take
years for a vaccine to reach market. However, a Department of Health
and Human Services initiative known as Project Bioshield was
implemented to expedite the process. Under its directive, the same
mechanism may accelerate MITRE's technology-derived antibody drugs.
With the research program in its third year, the team is shifting from
the research stage to the process development stage. Shortly, they
plan to test the stability of the B cell lines, large scale production
of antibodies, and other aspects of development. They also can license
this technology for use against toxins and infectious diseases.
Although currently focusing on the avian influenza strain, the team
expects this cost-effective concept can apply to other targets.
"All you need to decide is what the source of the protein target will
be," says Arroyo. "We've chosen avian flu strains, but down the road
any specific target can be chosen, such as proteins from other viruses
like Ebola, Marburg, or Hantaviruses."
"Ultimately, it is hoped that this technology will enable large-scale
production of therapeutic monoclonal antibodies from selected B cell
lines," says Steinberg. "Such B cell lines could be developed so that
antibodies would be produced against many select agents." According to
Arroyo, the stable antibodies can then be frozen and become part of
the national strategic stockpile to help protect against viruses,
bacteria, or targets of interest to biodefense.
—by Elvira Caruso
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci